本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、现金管理概述 （一）现金管理目的 为提高公司资金使用效率，增加资金收益，在确保公司正常经营和资金安全的 前提下，公司及全资子公司、控股子公司拟使用暂时闲置自有资金进行委托理财。 上述行为不会影响公司主营业务的发展，也不存在损害股东利益的情形。 证券代码：603309 证券简称：维力医疗 公告编号：2026-006 广州维力医疗器械股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 （二）现金管理额度 公司及全资子公司、控股子公司拟合计使用闲置自有资金不超过 3.5 亿元的额 度进行现金管理，额度可以在 12 个月内滚动使用，以 12 个月内任一时点的理财产 委托理财产品种类：风险较低、流动性较好、安全性高的中、低风险理财 产品，包括但不限于存款产品、收益凭证、理财产品等。 委托理财金额：不超过 3.5 亿元人民币 履行的审议程序：广州维力医疗器械股份有限公司（以下简称"公司"、 "维力医疗"）于 2026 年 1 月 9 日召开的第五届董事会第十九次会议 ...

证券代码：603309 证券简称：维力医疗 公告编号：2026-005 广州维力医疗器械股份有限公司 第五届董事会第十九次会议决议公告 （二）审议通过《关于公司 2026 年度日常关联交易预计的议案》。 因日常生产经营活动和业务发展需要，公司拟与相关关联方进行采购材料、 销售产品和商品的日常关联交易。（具体内容详见同日刊登在《中国证券报》 1 《上海证券报》《证券时报》及上海证券交易所网站（www.sse.com.cn）的《维 力医疗关于 2026 年度日常关联交易预计的公告》（公告编号：2026-007））。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广州维力医疗器械股份有限公司（以下简称"公司"）第五届董事会第十九 次会议的会议通知和材料于2026年1月4日以电子邮件方式发出，会议于2026年1 月9日上午10点在公司会议室以现场和通讯相结合的方式召开，会议由董事长向 彬先生主持，会议应出席董事7名，亲自出席董事7名。其中，董事段嵩枫先生、 独立董事芦春斌先生、独立董事欧阳文晋先生、独立董事臧 ...

Group 1 - The core announcement is that Guangzhou Welly Medical Instrument Co., Ltd.'s wholly-owned subsidiary, Hainan Welly Medical Technology Development Co., Ltd., has had its product, a disposable hydrophilic coated visible nasogastric tube, included in the Hainan Province Innovation Medical Device Product Directory (Fourth Batch) [2][3] Group 2 - The inclusion of the innovative product in the directory is a recognition of the product's technological advancement and innovation, which is expected to enhance the company's brand awareness and market competitiveness [3] - The selected product will benefit from a series of supportive policies aimed at promoting the development of innovative medical devices in Hainan Province, positively impacting future sales [3] - The company plans to leverage this inclusion as an opportunity to increase its research and development efforts in innovative medical devices, enhance its independent innovation capabilities, and contribute to the high-quality development of the regional biopharmaceutical industry [3]

Group 1 - The core point of the article is that Weili Medical's wholly-owned subsidiary, Hainan Weili Medical Technology Development Co., Ltd., has had its hydrophilic coated visible nasogastric tube included in the fourth batch of innovative drug and medical device product catalog in Hainan Province, which will benefit sales through local innovation support policies [2] Group 2 - The inclusion of the product in the catalog is expected to provide long-term benefits for the company's sales [2]

Core Viewpoint - Weili Medical (603309.SH) announced that the sixth batch of national medical consumables procurement does not involve Wolf and Medical products, indicating a potential impact on the company's financials due to the acquisition of Wolf and Medical [2] Group 1: Financial Implications - The company has preliminarily assessed that goodwill arising from the acquisition of Wolf and Medical has shown signs of impairment based on the operational status projected for 2025 [2] - To reflect the financial status and asset value more objectively and fairly, the company plans to recognize goodwill impairment for the fiscal year 2025, with the final impairment amount to be determined by an evaluation and auditing firm [2] - The financial data for Q4 2025 has not yet been disclosed, and stakeholders are advised to pay attention to subsequent periodic reports for detailed descriptions and breakdowns of quarterly data [2] Group 2: Performance Forecast - The 2025 performance forecast data provided by the company is based on preliminary calculations from the finance department, with the accurate financial data to be confirmed in the officially disclosed audited annual report for 2025 [2]

三、风险提示 海南省创新药械产品目录清单的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、基本情况 广州维力医疗器械股份有限公司（以下简称"公司"）全资子公司海南维力 医疗科技开发有限公司（以下简称"海南维力"）于近日收到《海南省工业和信 息化厅 海南省卫生健康委员会 海南省医疗保障局 海南省药品监督管理局关于 印发<海南省创新药械产品目录清单(第四批)>的通知》，海南维力产品一次性使 用亲水涂层可视鼻胃肠管（琼械注准20252140055）入选海南省创新药械产品目 录清单(第四批)。 二、对公司的影响 上述创新产品入选海南省创新药械产品目录清单，是对公司产品技术先进性、 创新性的认可，有助于提高公司品牌知名度及市场竞争力，入选产品将享受海南 省促进创新药械发展的一系列支持政策，对入选产品未来的销售具有积极影响。 公司将借本次入选为契机，继续加大创新药械的研发力度，增强自主创新能 力，积极响应并融入地方产业发展战略，为促进区域生物医药产业的高质量发展 贡献企业力量。 证券代码：603309 证券简称：维力医疗 公告编 ...

Core Viewpoint - Weili Medical's subsidiary, Hainan Weili, has been recognized for its innovative product, the hydrophilic coated visible nasogastric tube, which has been included in the fourth batch of the Hainan Province innovative medical device product catalog [1] Group 1: Product Recognition - The inclusion of the hydrophilic coated visible nasogastric tube in the Hainan Province innovative medical device product catalog signifies recognition of the product's technological advancement and innovation [1] - This recognition is expected to enhance the company's brand awareness and market competitiveness [1] Group 2: Support Policies - The selected product will benefit from a series of supportive policies aimed at promoting the development of innovative medical devices in Hainan Province, which is anticipated to positively impact future sales [1] Group 3: R&D Commitment - The company plans to leverage this recognition to further increase its research and development efforts in innovative medical devices, aiming to strengthen its independent innovation capabilities [1] - The company is committed to aligning with local industrial development strategies to contribute to the high-quality development of the regional biopharmaceutical industry [1]

Core Viewpoint - The company, Weili Medical, has received recognition for its innovative product, the hydrophilic coated visual nasogastric tube, which has been included in the fourth batch of the Hainan Province innovative medical device product catalog, enhancing its brand visibility and market competitiveness [1] Group 1 - Weili Medical's wholly-owned subsidiary, Hainan Weili Medical Technology Development Co., Ltd., has been notified of its product's inclusion in the Hainan Province innovative medical device product catalog [1] - The inclusion of the innovative product is a recognition of the company's technological advancement and innovation [1] - The selected product will benefit from a series of supportive policies aimed at promoting the development of innovative medical devices in Hainan Province, positively impacting future sales [1] Group 2 - The company plans to leverage this inclusion as an opportunity to increase its research and development efforts in innovative medical devices [1] - The company aims to enhance its independent innovation capabilities and actively respond to local industrial development strategies [1] - The company is committed to contributing to the high-quality development of the regional biopharmaceutical industry [1]

Core Viewpoint - The company, Weili Medical, has announced that its wholly-owned subsidiary, Hainan Weili Medical Technology Development Co., Ltd., has received notification regarding the inclusion of its product, the single-use hydrophilic coated visible nasogastric tube, in the fourth batch of the Hainan Province innovative medical device product catalog [1] Group 1 - Weili Medical's product has been officially recognized and included in the Hainan Province innovative medical device product catalog [1] - The product is identified as a single-use hydrophilic coated visible nasogastric tube with the registration number Qiong Medical Approval 20252140055 [1] - This inclusion may enhance the company's market presence and potential sales in the region [1]

资金面上看，维力医疗近5日主力资金总体呈净流出状态，累计净流出1105.06万元，其中，上一交易日 主力资金全天净流出812.35万元。（数据宝） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 证券时报•数据宝统计显示，今日公布2025年业绩预告公司中，截至发稿股价较为强势的有川金诺、中 科蓝讯、高能环境等，股价分别上涨11.14%、10.77%、6.40%。 维力医疗股价出现异动，截至今日9时32分，股价下跌7.29%，成交424.10万股，成交金额5453.97万 元，换手率为1.45%，公司发布的最新业绩预告显示，预计2025年实现净利润7500.00万元—9500.00万 元，净利润同比下降57.00%—66.00%。 ...